Hi Friends
Just some update on the beta drugs:
(1) After recommendation, the stock price has shot up almost 50%. I have got several queries if the stock is still good to buy.
Since I am not a SEBI registered research analyst, I can't suggest buying/selling. Company for the H1 2018 has posted outstanding result with a Net profit of 3.4Cr vs last year H1 17 of 0.4Cr..EPS of H1 18 is ~4 while the company has already issued guidance that it expects its full-year profit to be ~8cr which would imply EPS of ~9.
Given the stock price ~90, it's clear that the stock is still very cheap esp with P/E of 10 based upon FY18 earnings. In Industry where average P/E of pharma is ~20-30, there is still room for 100% upside on this at least from the current level if everything goes as planned by the company
(2) The company mentioned that there is further upside to 8cr if its able to complete the Adley formulations. Few weeks after results were published, the company announced that it has completed the acquisition. This will add further uptick to the revenue.
Regards
Microcapblaster
Just some update on the beta drugs:
(1) After recommendation, the stock price has shot up almost 50%. I have got several queries if the stock is still good to buy.
Since I am not a SEBI registered research analyst, I can't suggest buying/selling. Company for the H1 2018 has posted outstanding result with a Net profit of 3.4Cr vs last year H1 17 of 0.4Cr..EPS of H1 18 is ~4 while the company has already issued guidance that it expects its full-year profit to be ~8cr which would imply EPS of ~9.
Given the stock price ~90, it's clear that the stock is still very cheap esp with P/E of 10 based upon FY18 earnings. In Industry where average P/E of pharma is ~20-30, there is still room for 100% upside on this at least from the current level if everything goes as planned by the company
(2) The company mentioned that there is further upside to 8cr if its able to complete the Adley formulations. Few weeks after results were published, the company announced that it has completed the acquisition. This will add further uptick to the revenue.
Regards
Microcapblaster
No comments:
Post a Comment
Note: only a member of this blog may post a comment.